{
}
Barclays analyst Luke Sergott has raised the target price for Guardant Health (GH) from $55.00 to $60.00, maintaining an "Overweight" rating, reflecting confidence in the stock's potential. The average target price from 22 analysts is $56.39, indicating a 17.22% upside from the current price of $48.11. Additionally, the consensus recommendation from 26 brokerage firms is 1.8, suggesting an "Outperform" status.
UBS analyst Dan Leonard has raised the price target for Guardant Health (GH) from $65.00 to $70.00, maintaining a "Buy" rating, reflecting positive market expectations. The average target from 22 analysts is $56.39, indicating a potential upside of 15.48% from the current price of $48.83. Guardant Health holds an average brokerage recommendation of 1.8, suggesting an "Outperform" status.
Guardant Health (GH) has received a price target increase from UBS, now set at $70, following strong quarterly results that exceeded expectations. The company reported a 21% year-over-year revenue growth to $203.5 million and raised its full-year revenue guidance to $880-$890 million, driven by improved oncology volume and pricing. Despite a projected downside in fair value, analysts maintain an "Outperform" rating, reflecting confidence in the company's strategic collaborations and market position.
Barclays has raised its price target for Guardant Health (GH) to $60, citing positive developments in its ignition business and upgraded projections for its Shield and Oncology segments. Analysts forecast an average target price of $55.29, indicating a potential upside from the current price of $47.23, while the company reported a 21% year-over-year revenue growth to $203.5 million in Q1 2025.
Guardant Health Inc
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
barclays raises guardant health stock target price to sixty dollars
18:48 01.05.2025
guardant health receives price target increase to seventy dollars from ubs
18:21 01.05.2025
guardant health reports strong earnings and receives price target increase from ubs
15:40 01.05.2025
barclays raises guardant health price target amid positive business developments
10:46 01.05.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: